The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it does have a lot more utility in the research setting in terms of looking at how carriers versus non-carriers respond to certain treatments and helping us understand that carriers you know may respond differently to different lifestyle interventions may have an earlier onset compared to people who don't have it but ultimately end up with the same disease
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.